Amgen Inc. (NASDAQ:AMGN) Shares Sold by Live Oak Investment Partners

Live Oak Investment Partners lowered its holdings in Amgen Inc. (NASDAQ:AMGN) by 19.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 616 shares of the medical research company’s stock after selling 149 shares during the period. Live Oak Investment Partners’ holdings in Amgen were worth $161,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Unionview LLC increased its holdings in shares of Amgen by 3.8% in the third quarter. Unionview LLC now owns 876 shares of the medical research company’s stock valued at $282,000 after buying an additional 32 shares in the last quarter. Avidian Wealth Enterprises LLC grew its holdings in shares of Amgen by 0.6% in the 3rd quarter. Avidian Wealth Enterprises LLC now owns 5,863 shares of the medical research company’s stock worth $1,889,000 after acquiring an additional 33 shares during the last quarter. Beacon Financial Advisory LLC grew its holdings in shares of Amgen by 4.6% in the 3rd quarter. Beacon Financial Advisory LLC now owns 769 shares of the medical research company’s stock worth $248,000 after acquiring an additional 34 shares during the last quarter. Semus Wealth Partners LLC raised its position in shares of Amgen by 2.3% during the third quarter. Semus Wealth Partners LLC now owns 1,531 shares of the medical research company’s stock worth $493,000 after purchasing an additional 35 shares during the period. Finally, Connable Office Inc. lifted its holdings in shares of Amgen by 0.5% during the third quarter. Connable Office Inc. now owns 6,972 shares of the medical research company’s stock valued at $2,246,000 after purchasing an additional 37 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

AMGN has been the topic of a number of analyst reports. Citigroup reissued a “neutral” rating on shares of Amgen in a research note on Wednesday, February 5th. Wolfe Research initiated coverage on shares of Amgen in a research report on Friday, November 15th. They issued a “peer perform” rating on the stock. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Truist Financial lowered their price objective on shares of Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a research report on Wednesday, January 8th. Finally, William Blair reaffirmed an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Amgen currently has an average rating of “Hold” and a consensus target price of $314.09.

Amgen Stock Performance

Shares of AMGN opened at $312.19 on Wednesday. The firm has a market cap of $167.71 billion, a price-to-earnings ratio of 41.35, a price-to-earnings-growth ratio of 2.63 and a beta of 0.56. The company’s fifty day moving average is $282.76 and its 200-day moving average is $299.66. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Equities analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.05%. Amgen’s dividend payout ratio (DPR) is currently 126.09%.

Insiders Place Their Bets

In other Amgen news, EVP David M. Reese sold 25,225 shares of the company’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the sale, the executive vice president now directly owns 36,922 shares in the company, valued at $11,240,533.68. This represents a 40.59 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now owns 7,210 shares in the company, valued at $2,195,228.70. The trade was a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 69,341 shares of company stock valued at $20,644,335 over the last 90 days. 0.69% of the stock is currently owned by company insiders.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.